APG-2575 Clinical Trials

4 actively recruiting trials across 1 location

▼ -1 trial since August 2026

Pipeline

Phase 2: 1Phase 1/2: 3

Top Sponsors

Ascentage Pharma Group Inc.4

Indications

Cancer3
SLE1
Non-Hodgkins Lymphoma1
T-Prolymphocytic Leukemia1
Lupus1

Other3 trials

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Phase 1/2

APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors

Phase 1/2

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Phase 1/2

Houston, Texas1 trial

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

MD Anderson

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.